Literature DB >> 16429115

Pubertal androgen therapy in boys.

Alan D Rogol1.   

Abstract

Anabolic-androgenic steroids (AAS) are necessary for normal male sexual differentiation and development and pubertal development. Androgen therapy is appropriate for boys with delayed development (constitutional delay of growth and puberty, CDGP) as well as those with primary or secondary hypogonadism. The principal goal is to restore the serum testosterone (T) level to the normal range at each stage of adolescent development and then to the normal adult range if the hypogonadism is permanent. In addition the levels of dihydrotestosterone and estradiol should also be within the normal range. One should be able to do that with a wide variety of androgen preparations-injectable, implantable, and cutaneous patches or gels. However, during the transition from prepubertal to adult it is difficult to reliably deliver the relatively small doses of T necessary for adolescent development using any of the cutaneous preparations. Androgen therapy should permit normal linear growth (including the adolescent growth spurt), adolescent sexual development, and the attainment of normal body composition including lean body mass, bone and the appropriate regional distribution of body fat as well as the psychological development appropriate for the stage of adolescent development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16429115

Source DB:  PubMed          Journal:  Pediatr Endocrinol Rev        ISSN: 1565-4753


  11 in total

Review 1.  Etiology and treatment of hypogonadism in adolescents.

Authors:  Vidhya Viswanathan; Erica A Eugster
Journal:  Pediatr Clin North Am       Date:  2011-10       Impact factor: 3.278

2.  Leydig cell transplantation restores androgen production in surgically castrated prepubertal rats.

Authors:  Jie Sun; Ye-Bin Xi; Zhong-De Zhang; Ping Shen; Huai-Yuan Li; Min-Zhi Yin; Wei-Yi Li; Cheng-Ren Shi
Journal:  Asian J Androl       Date:  2009-05-18       Impact factor: 3.285

Review 3.  Etiology and treatment of hypogonadism in adolescents.

Authors:  Vidhya Viswanathan; Erica A Eugster
Journal:  Endocrinol Metab Clin North Am       Date:  2009-12       Impact factor: 4.741

4.  Differentiation of human umbilical cord mesenchymal stem cells into Leydig-like cells with defined molecular compounds.

Authors:  Weiping Ji; Yong Chen; Long Wang; Zhangye Xu; Jahanzeb Ahmed; Renshan Ge; Maoping Chu; Xiaoling Guo
Journal:  Hum Cell       Date:  2020-02-07       Impact factor: 4.374

5.  Mesenchymal stem cells from human umbilical cord ameliorate testicular dysfunction in a male rat hypogonadism model.

Authors:  Zhi-Yuan Zhang; Xiao-Yu Xing; Guan-Qun Ju; Liang Zhong; Jie Sun
Journal:  Asian J Androl       Date:  2017 Sep-Oct       Impact factor: 3.285

6.  Differentiation of human adipose derived stem cells into Leydig-like cells with molecular compounds.

Authors:  Yong Chen; Chao Li; Weiping Ji; Long Wang; Xianwu Chen; Shenzhi Zhao; Zhangye Xu; Renshan Ge; Xiaoling Guo
Journal:  J Cell Mol Med       Date:  2019-07-10       Impact factor: 5.310

Review 7.  Androgen Treatment in Adolescent Males With Hypogonadism.

Authors:  Rodolfo A Rey; Romina P Grinspon
Journal:  Am J Mens Health       Date:  2020 May-Jun

Review 8.  Testosterone Use in Adolescent Males: Current Practice and Unmet Needs.

Authors:  Maria Vogiatzi; James P Tursi; Jonathan S Jaffe; Sue Hobson; Alan D Rogol
Journal:  J Endocr Soc       Date:  2020-10-30

Review 9.  Recent advancement in the treatment of boys and adolescents with hypogonadism.

Authors:  Rodolfo A Rey
Journal:  Ther Adv Endocrinol Metab       Date:  2022-01-05       Impact factor: 3.565

10.  Progression of puberty after initiation of androgen therapy in patients with idiopathic hypogonadotropic hypogonadism.

Authors:  Bindu Kulshreshtha; Rajesh Khadgawat; Nandita Gupta; Ariachery Ammini
Journal:  Indian J Endocrinol Metab       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.